Experienced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome

Dr. Amitabha Mazumder

Hematology Oncology | Oncology
The Oncology Institute Ca, A Professional Corporation
50 Bellefontaine St, Suite 401, 
Pasadena, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
The Oncology Institute Ca, A Professional Corporation
50 Bellefontaine St, Suite 401, 
Pasadena, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amitabha Mazumder is a Hematologist Oncology specialist and an Oncologist in Pasadena, California. Dr. Mazumder is rated as an Experienced provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Multiple Myeloma, Superficial Thrombophlebitis, Thrombocytopenia, Anemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Specialist in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

THE ONCOLOGY INSTITUTE CA, A PROFESSIONAL CORPORATION
50 Bellefontaine St, Suite 401, Pasadena, CA 91105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 2
A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis
A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Other, Drug
Study Drugs: Selinexor, Ruxolitinib
Study Phase: Phase 3
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drug: Rilzabrutinib
Study Phase: Phase 3
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Enrollment Status: Terminated
Publish Date: August 23, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Pembrolizumab
Study Phase: Phase 2
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Drugs: Melphalan Flufenamide (Melflufen), Dexamethasone
Study Phase: Phase 2
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Enrollment Status: Terminated
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: MT-3724
Study Phase: Phase 1/Phase 2
A Phase 2a Open-label Study to Investigate Safety and Tolerability (Including the Maximum Tolerated Dose), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination With Lenalidomide in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase 2a Open-label Study to Investigate Safety and Tolerability (Including the Maximum Tolerated Dose), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination With Lenalidomide in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: MT-3724
Study Phase: Phase 2
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: MT-3724
Study Phase: Phase 2
A Phase II, Trial of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
A Phase II, Trial of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Enrollment Status: Terminated
Publish Date: February 24, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

23 Total Publications

Towards next generation digital twin in robotics: Trends, scopes, challenges, and future.
Towards next generation digital twin in robotics: Trends, scopes, challenges, and future.
Journal: Heliyon
Published: November 19, 2022
Similar Doctors
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Frank K. Mori
Oncology | Hematology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Frank K. Mori
Oncology | Hematology
390 North Pacific Coast Highway, Suite 1020, 
El Segundo, CA 
 (20.7 miles away)
310-649-7222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Frank Mori is a Hematologist and an Oncologist in El Segundo, California. Dr. Mori is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia. Dr. Mori is currently accepting new patients.

Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Jason S. Ho
Oncology | Hematology Oncology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Jason S. Ho
Oncology | Hematology Oncology
50 Alessandro Place, Suite 310, 
Pasadena, CA 
 (0.1 miles away)
626-288-0008
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Ho is a Hematologist Oncology specialist and an Oncologist in Pasadena, California. Dr. Ho is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Ho is currently accepting new patients.

Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Lasika C. Seneviratne
Oncology | Hematology Oncology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Lasika C. Seneviratne
Oncology | Hematology Oncology
1245 Wilshire Boulevard, Suite 303, 
Santa Monica, CA 
 (8.4 miles away)
213-977-1214
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lasika Seneviratne is a Hematologist Oncology specialist and an Oncologist in Santa Monica, California. Dr. Seneviratne is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Agranulocytosis, and Inflammatory Breast Cancer. Dr. Seneviratne is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mazumder's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 115 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile